Cabaletta Bio Reports Positive Early Clinical Data for rese-cel in Pemphigus Vulgaris Trial
Summary
Cabaletta Bio announced promising clinical and safety data from its RESET-PV trial for rese-cel in pemphigus vulgaris patients, showing biologic and clinical activity without preconditioning.
Key Events
-
Positive Clinical Activity
Rese-cel demonstrated clear biologic and clinical activity in 4 refractory pemphigus vulgaris patients at the lowest dose without preconditioning, with 2 of 4 showing compelling clinical activity through 6 months follow-up.
-
Favorable Safety Profile
Only one Grade 1 cytokine release syndrome (CRS) event was observed in the RESET-PV trial, with no immune effector cell-associated neurotoxicity syndrome (ICANS).
-
Advancement to Higher Doses
Based on the safety profile, multiple additional patients have been enrolled in a higher dose cohort for the RESET-PV trial, with durability data anticipated in the second half of 2026.
-
Upcoming Lupus Data
The initial dose cohort for the RESET-SLE trial (lupus) is fully enrolled, with initial data at the first dose anticipated in the first half of 2026.
Analysis
This 8-K provides significant positive early clinical data for Cabaletta Bio's lead candidate, rese-cel, in pemphigus vulgaris. The observation of clear biologic and clinical activity, with two of four patients demonstrating compelling clinical activity and three remaining off immunomodulators and steroids, is a strong signal of efficacy. Crucially, this was achieved at the lowest dose without preconditioning, and with a favorable safety profile (only one Grade 1 CRS event). This positive development is particularly important given the company's previously disclosed "going concern" warning in its 2025 annual report and the recent shareholder proposal to increase authorized shares, indicating a need for future financing. Strong clinical data like this can significantly improve the company's position for future capital raises and de-risk its development pipeline. The advancement to higher dose cohorts and anticipated data from the RESET-SLE trial further underscore the positive momentum.
At the time of this filing, CABA was trading at $3.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $327.3M. The 52-week trading range was $1.11 to $3.78. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.